Atomoxetine for cognitive impairment in Behcet's disease

Evaluation the effects of atomoxetine on the improvement of cognitive impairment in Behcet’s disease patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211206053288N1

Enrollment

Registered

2022-02-20

Start date

2022-04-04

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Behcet's disease. Condition 2: Cognitive impairment. Behcet's disease Mild cognitive impairment, so stated

Interventions

Intervention 1: Intervention group: initially, Atomoxetine capsule (Amin pharmaceutical company) will be administered 40mg/day. After 3 days will be increased to 40mg, twice a day and then continued f

Eligibility

Sex/Gender

All

Age

17 Years to 85 Years

Inclusion criteria

Inclusion criteria: Individuals diagnosed with Behcet's disease according to ICBD (International Criteria for Behcet's Disease) criteria Presence of cognitive impairment detected by following tests: Forward digit span, Backward digit span, Trail making A, Trail making B, Verbal fluency

Exclusion criteria

Exclusion criteria: History of cognitive impairment before affected by Behcet's disease Substance use History of adverse reactions to Atomoxetine

Design outcomes

Primary

Measure	Time frame
Score of following cognitive tests: Forward digit span, Backward digit span, Trail making A, Trail making B, Verbal fluency. Timepoint: before intervention and 10 weeks after intervention. Method of measurement: cognitive tests: Forward digit span, Backward digit span, Trail making A, Trail making B, Verbal fluency.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMalekfarhad Malek

Tehran University of Medical Sciences

malekmf@sina.tums.ac.ir+98 21 5541 9151

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026